StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX – Get Rating) in a research note issued to investors on Sunday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.
Separately, Zacks Investment Research cut DURECT from a hold rating to a sell rating in a report on Thursday, May 5th.
Shares of DRRX opened at $0.42 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 7.60 and a current ratio of 7.83. DURECT has a 52-week low of $0.37 and a 52-week high of $1.85. The business’s 50 day moving average price is $0.52 and its two-hundred day moving average price is $0.76. The firm has a market cap of $95.36 million, a PE ratio of -2.62 and a beta of 1.47.
In other news, Director Judith J. Robertson acquired 200,000 shares of the business’s stock in a transaction that occurred on Monday, March 14th. The stock was bought at an average price of $0.59 per share, with a total value of $118,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders bought 236,700 shares of company stock valued at $132,505 in the last 90 days. Company insiders own 4.60% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Lion Point Capital LP raised its position in DURECT by 1.2% during the third quarter. Lion Point Capital LP now owns 15,486,004 shares of the specialty pharmaceutical company’s stock valued at $19,822,000 after purchasing an additional 177,435 shares during the period. BlackRock Inc. grew its stake in DURECT by 0.3% in the third quarter. BlackRock Inc. now owns 14,341,444 shares of the specialty pharmaceutical company’s stock worth $18,357,000 after purchasing an additional 39,239 shares in the last quarter. State Street Corp grew its stake in DURECT by 1.3% in the first quarter. State Street Corp now owns 3,977,581 shares of the specialty pharmaceutical company’s stock worth $2,665,000 after purchasing an additional 52,255 shares in the last quarter. Geode Capital Management LLC boosted its position in DURECT by 3.4% during the 3rd quarter. Geode Capital Management LLC now owns 3,873,448 shares of the specialty pharmaceutical company’s stock valued at $4,958,000 after acquiring an additional 126,212 shares in the last quarter. Finally, CM Management LLC boosted its position in DURECT by 20.9% during the 1st quarter. CM Management LLC now owns 3,535,732 shares of the specialty pharmaceutical company’s stock valued at $2,369,000 after acquiring an additional 610,537 shares in the last quarter. Institutional investors own 50.60% of the company’s stock.
About DURECT (Get Rating)
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
- Get a free copy of the StockNews.com research report on DURECT (DRRX)
- Roku Stock is Repricing and Resetting Itself
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Time to Ride These 3 Mid Cap Momentum Plays
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.